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Abstract
The clinical use of blood has a long history, but its apparent stability belies the complexity 
of contemporary practices in this field. In this article, we explore how the production, 
supply and deployment of blood products are socially mediated, drawing on theoretical 
perspectives from recent work on ‘tissue economies’. We highlight the ways in which 
safety threats in the form of infections that might be transmitted through blood and 
plasma impact on this tissue economy and how these have led to a revaluation of donor 
bodies and restructuring of blood economies. Specifically, we consider these themes in 
relation to the management of recent threats to blood safety in the United Kingdom. 
We show that the tension between securing the supply of blood and its products and 
ensuring its safety may give rise to ethical concerns and reshape relations between 
donor and recipient bodies.
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Introduction: perspectives on blood and tissue 
economies
Modern biomedicine is dependent upon a range of human tissues and cells, which have 
applications in transfusion medicine, transplantation medicine and regenerative medi-
cine. Blood has long been used in medicine and continues to have diverse applications in 
most health-care systems for emergencies and in planned care, hence its description by 
the World Health Organization (WHO) (2004) as an ‘essential health technology’. 
Although the use of blood in medicine is an established practice, its apparent stability 
belies the complexity and change that characterise this field. We aim to explore some of 
the ways in which the production, supply and deployment of blood has been transformed, 
drawing on theoretical perspectives from recent work on ‘tissue economies’.
Given the expanded repertoire of uses for human tissues in the 21st century, it has 
been argued that there is a need to consider the ways in which ‘medical systems that 
exchange and circulate tissues are also social systems’ (Waldby, 2002: 309). Increasingly, 
biotechnology has been applied to tissues extracted from humans with the intention of 
enhancing their applications in the clinic and in research. According to Waldby (2002), 
‘Biovalue refers to the yield of vitality produced by the biotechnical reformulation of 
living processes’ (p. 310). As new forms of organisation have sprung up with a view to 
mobilising the potential value of these developments, sociologists and anthropologists 
have explored the fields of enterprise generating biovalue. Here, there has been a particu-
lar focus on the novel ways of using human biological materials that have been devel-
oped in recent years, their social and economic entanglements and their wider ethical 
implications – be they embryos, foetuses or other tissues from the living or dead (see, for 
example, Kent, 2008; Palsson, 2009; Svendsen and Koch, 2008). The prevailing empha-
sis on new biological materials or innovative applications is in keeping with recent influ-
ential accounts of biopolitics and the transformative potential of biosciences (Rose, 
2007). Yet, use of blood associated with more established technologies remains highly 
significant, both in clinical and in economic terms.
As with some newer kinds of tissue donation, ideals of altruism are influential in 
public policy about blood services and ‘promulgated by professional groups and policy 
makers’ in these fields (Shaw, 2011: 299). These ideals inform the narrative appeals of 
organisations involved in soliciting blood (and other tissue) donations (Healy, 2006). 
While Richard Titmuss’ influential work on gift relationships has been a productive point 
of reference for thinking about blood services, perspectives from recent work on tissue 
economies also underline the difficulties in securing separation of human tissues from 
the commercial realm (Hoeyer, 2009). This difficulty can be understood in the light of a 
broader argument that objects (including biological objects) often have rather complex 
lives in the social world, so that ‘the commodity is not one kind of thing rather than 
another but one phase in the life of some things’ (Appadurai, 1986: 17, cited in Waldby 
and Mitchell, 2006: 25). Notwithstanding this complexity, principles of voluntariness 
and altruism weigh heavily in the field of blood donation (ISBT, 2006).
In this article, we argue that while traditional discourses continue to shape practices 
in some parts of the blood economy, the technical reformulation and division of blood 
into its component parts and the manipulation of those parts to create new products 
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generates new forms of biovalue. Layered onto these processes are complex and shift-
ing calculations about threats to blood safety, which in turn have implications for rela-
tions between donor and recipient bodies. We explore these themes with reference to 
several key policy issues faced by the blood services in the United Kingdom over the 
past 10 years. In developing our analysis, we shall draw on materials in the public 
domain, including documents from blood service organisations and regulators and gov-
ernment policies in the United Kingdom together with reports from international organ-
isations concerned with blood safety and supply, as well as on the scientific and social 
science literature.1
Deconstructing ‘blood’
The clinical application of blood has a long history. According to the Oxford English 
Dictionary, ‘Blood consists of a mildly alkaline aqueous fluid (plasma) containing red 
cells (erythrocytes), white cells (leucocytes), and platelets’ (Oxford English Dictionary, 
2011). The discovery of the part played by this fluid in maintaining key physiological 
processes and of the harnessing of blood for use in medical treatments has been well 
described in the popular book by Douglas Starr, as well as in the professional literature 
(Giangrande, 2000; Starr, 1998). The first blood banks were established in the 1940s, 
with more systematic services to provide blood to hospitals being set up in the middle 
part of the 20th century. In the early years of transfusion practice, whole blood was 
stored and transfused. A reliance on whole blood transfusion changed with the develop-
ment of fractionating techniques in the United States through the following decades; 
developments in the 1950s and 1960s eventually allowed for the possibility of manufac-
turing products from plasma proteins in one place, storing them until required and ship-
ping them to where they were needed. Subsequent developments allowed for blood to 
be broken down into other components. These components have specific therapeutic 
characteristics, and their storage requirements also vary. Over some decades, the use of 
‘whole blood’ transfusion has reduced in countries that have resources to process and 
separate blood (Jersild and Hafner, 2008). Contemporary transfusion medicine is char-
acterised by the use of different components of the blood, administered to patients 
according to their clinical needs. As well as allowing for better targeted interventions, 
this allows for each unit of donated blood to be deployed for the treatment of more than 
one patient. Blood increasingly came to be seen as a scarce resource that needed to be 
used in the most efficient ways possible. Hence, efficiency is a key principle underlying 
blood services today.
According to McClelland’s (2007) Handbook of Transfusion Medicine, a blood prod-
uct is ‘any therapeutic substance prepared from human blood’ (p. 1). Within this group 
are two categories: blood components and plasma (derived) products. Blood components 
may be prepared and administered separately in transfusion as platelets, red cells, white 
cells, cryoprecipitate and fresh frozen plasma (FFP). Plasma proteins once separated 
from blood may form the basis for a range of manufactured plasma-derived products. 
These include immunoglobulin products that have applications in the fields of immunol-
ogy, neurology, haematology and oncology; albumin that is used to help replace fluid 
loss after trauma and coagulation factors that are prescribed to alleviate the symptoms of 
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bleeding disorders. Although there have been many technical innovations in processing 
blood, the long endeavour to produce ‘artificial blood’ with similar functions to blood 
components for clinical use has not to date been successful.
Scientific and professional discourse distinguishes between plasma products and 
blood components. For the sake of clarity, we shall adopt these widely used terms in this 
article, and the term blood products will be used to refer collectively to all therapeutic 
products derived from blood and plasma. At the same time, we want to unpack the way 
that the use of these terms has the effect of implying that these are entirely different kinds 
of material, although they are of course all derived from human blood. In some contexts, 
two categories of donors have been created: the ‘blood donor’ who donates whole blood 
and the ‘plasma donor’ who provides plasma only, which is separated from the red blood 
cells at the point of donation.2 This binary categorisation becomes important when we 
consider that in key supplier countries, ‘plasma donors’ may receive payments (some-
times called compensation), whereas ‘blood donors’ may not.3 At the same time, 
exchange relationships between donor and recipient bodies have become complex, medi-
ated by a network of public and private and non-profit and for-profit institutions.
Demand in the blood economy
Dynamics of demand and supply in the blood economy have received little attention 
from those outside the blood services and plasma suppliers. However, we do know that 
there is a growing global demand for blood and plasma products. Data from the WHO 
(2004) Global Collaboration on Blood Safety give an indication of the volume of blood 
donated for therapeutic use in transfusion medicine: some 81 million units of whole 
blood and 20 million litres of plasma were donated in 2001–2002. More recent data point 
to an increased demand for plasma for fractionation (O’Mahony and Turner, 2010). 
Globally, the main applications of whole blood and its components are in the course of 
surgical procedures, including treatment of trauma patients, and in obstetric care with 
major bleeding during childbirth (Jersild and Hafner, 2008). Blood is also used in the 
treatment of medical diseases, especially haematological diseases such as thalassaemia. 
The use of whole blood, blood components and plasma-derived products does vary con-
siderably across different health systems, with more extensive use being made of a 
diverse range of blood products in countries with well-resourced health-care systems. 
Nevertheless, managing periodic or enduring shortages of blood and plasma is a key 
problem for blood services across the world. Worldwide, people with haemophilia have 
been the primary users of plasma products, as they are often prescribed coagulation fac-
tors on a long-term basis. However, global demand for plasma is today driven by the 
expansion of immunoglobulin therapies for diverse indications (Farrugia, 2006).
Whereas traditionally blood was thought of in terms of its direct clinical applications, 
its value is also related to the information that can be derived from it. Once extracted 
from the body, blood can be used for the purpose of diagnostic tests and for research. 
Discussion of these wider uses of blood goes beyond the scope of this study, but we want 
to highlight their close relationship. For example, organisations that obtain blood for use 
in transfusion or transplant medicine do routinely make it available to research organisa-
tions, especially if the blood is in some way ‘surplus’ to requirements or not suitable for 
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human application. As we have seen with the use of other human tissues, the framing of 
human biological material as surplus or as waste can facilitate the procurement of blood 
for research uses within a wider blood economy (Kent, 2008; Parry, 2006; Svendsen and 
Koch, 2008). Whether for research or therapeutic uses, the value of donated blood relates 
as much to the processes and standards of its procurement and storage as it does to its 
physical attributes.
From donor to recipient bodies
Public policies on blood donation in many regions have been shaped by notions of altru-
ism and common good – as well as by the need to provide resources for transfusion medi-
cine (Healy, 2006; Rabinow, 1999; Titmuss, 1970; WHO, 2005). In Britain, the ideals 
underlying the blood transfusion service chimed with the founding principles of the 
National Health Service (NHS), launched in 1948: that it should meet the needs of eve-
ryone, be free at the point of delivery, and be based on clinical need, not the ability to 
pay.4 The social and ethical importance of voluntary blood donation in Britain was 
famously expounded by Richard Titmuss (1970), whose work became influential inter-
nationally. The importance attributed to voluntary unpaid blood donation was for many 
years bolstered by a widespread belief that unpaid donation was the primary factor in 
securing blood safety. With the development of more sophisticated techniques for screen-
ing and viral inactivation of blood, safety in blood and plasma is now recognised to be a 
function of multiple factors, and consequently, the simple equating of safety with unpaid 
donation provides an inadequate account of contemporary realities. However, the ideal 
of ‘voluntary non-remunerated blood donation’ (VNRBD) remains influential and has 
become a touchstone for international initiatives on blood services (WHO, 1975, 2005, 
2009). Even so, blood donation has diverse meanings and framings in different parts of 
the world (Adams et al., 2009; Copeman, 2009). Our discussion here will focus on the 
blood economy in Europe and particularly on recent challenges faced by policymakers 
and regulators of blood safety in the United Kingdom. We will also refer to policies in 
the European Union (EU) that impact on blood safety and supply in the United Kingdom, 
as these are salient in both political and practical terms. We argue that there is increased 
instability in this area as relations between different actors in this field have become 
more politicised in recent years.
The association of blood banks in Europe with citizenship, solidarity and imagined 
national communities continued well beyond the post-war years when many such pro-
jects were first established (Rabinow, 1999). Policy on blood sourcing and supply con-
tinued to be framed in terms of ethical and political ideals well into the 21st century, as 
was evident in the discussions surrounding the enactment of the EU ‘Blood Directive’5 
(Farrell, 2006). Different interpretations of the moral and legal imperatives for VNRBD 
exist across the EU, as do the local practical arrangements of the various blood services: 
it is recognised that some organisations operating in the member states do provide some 
recompense for donors (European Commission, 2011; WHO, 2007). Notwithstanding 
these diverse practices, the principle of altruism remains very influential in blood policy 
and law in the EU. Another dimension of the influence of historical ideals in this domain 
is the suggestion that is sometimes made that blood donation is a ‘universal’ practice – in 
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the sense that all citizens can contribute to the common good by donating blood. In prac-
tice, increasingly stringent practices of donor selection and exclusion cut across claims of 
universalism in this domain (Valentine, 2005). In these and other respects, the ideological 
framing of blood policy is somewhat in tension with modern practices in this field.
Once the contamination of the blood supply with HIV and Hepatitis C in the 1980s 
and 1990s was taken up as a matter of public concern, accusations of irresponsibility 
levelled at health authorities and blood service authorities led to a series of investigations 
and inquiries in the countries affected (Feldman and Bayer, 1999). Although in the 
United Kingdom the government declined to take up the call made by patient groups for 
an official inquiry, an unofficial inquiry was eventually undertaken into these events in 
England and Wales (Archer et al., 2009). In addition, the Scottish government – having 
gained substantial devolved powers over health policy in recent years – set up an official 
inquiry in 2011.6 Both inquiries observed the extent to which blood and plasma supply 
had become more complex than patients had realised, with some products being sourced 
from outside the United Kingdom. Here as elsewhere, the iatrogenic disasters that 
impacted on blood services may have shifted public understandings so that blood came 
to be seen as ‘a distributor not [only] of health and benevolence but of risk and contami-
nation …’ (Waldby and Mitchell, 2006: 52, our brackets).
Following on from widespread recognition of the harm that occurred as a result of 
patients receiving infected blood in these years, policymakers and regulators have sought 
to take a precautionary stance to blood safety, seeking to anticipate and manage potential 
threats (Watkins et al., 2011). Although the threat of transfusion-transmitted HIV or 
Hepatitis C has greatly receded in countries with well-resourced health systems, the risk of 
blood-borne infections has become a part of the way that publics and politicians perceive 
blood. Public recognition of the capacity of blood to transmit feared infections does not 
replace but sits alongside an understanding of its capacity to sustain and even save lives. 
Coupled with the value placed on blood donation as ‘in itself’ a social good (pace Titmuss), 
this Janus-faced aspect of blood makes the regulation of safety in this field socially com-
plex and politically salient. Accordingly, those who claim a stake in these decisions include 
diverse groups going beyond the boundaries of those conventionally involved in patient 
safety. Blood safety has become a highly politicised issue characterised by litigation, tribu-
nals and inquiries and institutional and regulatory reform (Farrell, 2012).
In recent years, a wider range of interests has mobilised in relation to blood donation 
as well as blood services. There has been renewed interest on the part of those with an 
interest in blood donation and supply, those of donors, and of would-be donors who have 
been excluded, for example, men who have sex with men (Berner, 2011; Hurley, 2009).7 
There has also been a proliferation of patient groups representing people who are, or 
expect to be, recipients of plasma products. People with haemophilia, largely marginal-
ised and absent from decision-making in the past, now have organised input into policies 
on the procurement of blood and plasma products in some national health systems and in 
the political domain in the EU (O’Mahony and Turner, 2010). Suppliers of plasma prod-
ucts have sought to put forward their perspectives in the public domain, especially on the 
difficult balance that needs to be struck between safety and sufficiency of supply, and 
some have developed alliances with patients groups (Plasma Protein Therapeutics 
Association, 2011).
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Governing the blood supply in Europe
As well as being logistically complex, the supply of blood components and plasma prod-
ucts is politically sensitive in the EU. Two principles that have anchored political and 
policy discourse about the supply of blood for use in medicine are the ideals of voluntary 
blood donation already described above and the principle of ‘national self-sufficiency’. 
As we have seen, the view that blood donation should be voluntary and unremunerated 
features widely in public policy in many national health systems, as well as in EU law and 
in international safety initiatives. The principle of ‘self-sufficiency’ refers to the prefer-
ence of many professionals and politicians for the idea that blood used in a nation’s hos-
pitals should be sourced from donors in the same country. The idea that nations should 
develop their own blood sourcing and supply arrangements is often traced to a wish to 
avoid the exploitation of blood donors in developing countries (WHO, 1975). But as 
Farrugia has observed, policies of ‘self-sufficiency’ have also at times been associated 
with the belief that some donation systems were more likely to produce safe blood than 
others, and with assumptions that donors of some nationalities were less desirable than 
those of others in terms of blood safety: so on the one hand, the deployment of this frame-
work to public policy on the blood supply is resonant of some important ideals and beliefs, 
but on the other hand, it sometimes has undesirable associations of prejudice and dogma 
(Farrugia, 2009). In the context of globalisation, notions of ‘self-sufficiency’ are espe-
cially problematic and difficult to sustain in relation to the supply of blood and plasma.
The erosion of national ‘self-sufficiency’ of the blood and plasma products supply in 
the EU context arose from a number of factors that had differential effects on national 
systems. Among these were the advent of greatly increased demand for blood and plasma 
and limited investment in the infrastructure for the fractionating of plasma and making 
of products derived from it. Fractionation and manufacturing techniques were developed 
that required specialised infrastructure, and new organisations took on this specialised 
form of production. This infrastructure includes sourcing plasma outside Europe for the 
manufacture of products distributed worldwide. Once these changes were introduced, 
plasma products became more stable and acquired a longer shelf life – in contrast to 
other blood products – and could be more easily shipped to wherever they were required 
(Starr, 1998). In other words, these properties allowed for the production and the applica-
tion of plasma products to be decoupled, and this has allowed for the development of 
specialised organisations and supplier networks for them. As the supply of plasma prod-
ucts became internationalised, a number of specialist plasma producers were established, 
some of which were not-for-profit organisations and others for-profit companies. This 
situation contrasts with the supply of blood components, as national blood systems and 
not-for-profit agencies such as the Red Cross have controlled the supply to a greater 
extent. However, these not-for-profit blood suppliers fear that arrangements for supply-
ing blood components are liable to change, as entry of for-profit companies into this 
market threatens the stability and safety of supply that existing providers currently offer 
(European Blood Alliance, 2009).
So while ‘fresh plasma’ – that is plasma extracted from donated blood, frozen and 
used within short time scales – continued to be produced by various blood services, 
the manufacture of products derived from plasma was taken on by specialist 
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producers. For-profit fractionators represent the great majority of fractionating capability 
worldwide, with not-for-profit agencies accounting for around one-fifth of this activity 
(Australian Government, 2006). Worldwide, the United States accounts for approxi-
mately 70 per cent of plasma collected, and within the United States, the bulk of plasma 
collected comes from paid plasma donors (Australian Government, 2006: 70). This reli-
ance on US-sourced plasma extends to Europe, including countries that have made 
extensive efforts to boost their plasma collection capacities. The political sensitivity of 
relying on paid plasma donors to supply health-care requirements in the EU is such that 
it is difficult to confirm up to date figures for the plasma economy. However, data from 
the 1990s point to over 50 per cent of the EU market being sourced from plasma col-
lected in the United States (Farrell, 2006).
It will be evident from this brief outline that the plasma economy does not conform 
to notions of national self-sufficiency of supply or of unpaid donation but rather it con-
tradicts these. These principles remain influential, however, and accordingly, some 
countries have sought to retain their own plasma collecting and fractionating capabili-
ties. Nevertheless, the collection and fractionation of plasma and the production of 
plasma derivatives usually involve considerable interpenetration of private and public 
agencies and transactions. For example, in the United Kingdom, the company Bio 
Products Laboratory Limited (BPL) supplies plasma products internationally on a com-
mercial basis, in addition to being a supplier for the NHS. The links between public and 
private sectors intensified with the purchase by the Department of Health of a US 
plasma company in 2002, with the aim of securing supply of plasma for the United 
Kingdom in the wake of alarm about the implications of variant Creutzfeldt–Jakob dis-
ease (vCJD) (House of Lords, 2002). Other national plasma providers, such as Sanquin 
in the Netherlands, also offer contract fractionation services to countries that do not 
have their own suppliers. In short, the plasma and blood economies are networked and 
interconnected, characterised by cross border flows of products that are essential to 
deliver modern health care.
Arrangements for the production of plasma products contrast with the production of 
blood components – which can be stored for shorter periods of time – for which local or 
regional supply remains the norm. Blood components are usually supplied from a point 
relatively close to hospitals where they will be used. In contrast, the production of plasma 
derivatives is a global business. This state of affairs is sometimes summed up in the 
phrase ‘blood is national, plasma is global’ (Farrugia, 2009: 125). Thus, there are com-
plex and multiple chains for the supply of a range of products derived from human blood 
and used in medicine. The procurement and supply of these are shaped to some extent by 
national governments and regulatory bodies and by coordinating bodies internationally. 
However, they are also shaped by the global plasma industry. A third factor is that 
responses to blood safety threats, which are often unpredictable, affect market demand 
and supply for these products and their value.
What kind of (bio)value is produced from blood?
As with other tissues and cells, the therapeutic use of blood is mediated through a range 
of technological interventions. Although blood transfusion originally involved the use of 
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whole blood, as we have seen, it is now more usual for blood to be in the form of compo-
nents or plasma products. In common with many other biological tissues, the raw material 
of donated blood requires an investment of effort and resources to be formulated in the 
ways that are required for its diverse applications (Hoeyer, 2009; Waldby, 2002: 310).
Given the moral sensitivities about discussing blood and its derivatives in the same 
terms that are used to discuss the prices paid for commodities such as oil, foods or met-
als, there are some difficulties associated with making an assessment of the monetary 
value of blood. The approach taken here will be to look at some examples, rather than to 
endeavour to set out a complete picture of the payments associated with the supply of 
blood products. As we have seen, there are a range of suppliers for blood and plasma 
products, some of which are run by national or regional health services and others by 
separate commercial bodies, not-for-profit agencies or hybrid organisations. As with the 
sourcing of blood, transactions relating to the use of blood have long been subject to 
social and ethical constraints. Influential international declarations, such as the WHO’s 
World Health Assembly Resolution of 1975 and the Melbourne Declaration of 2009, as 
well as national and international laws and guidelines in many countries prohibit the 
‘commodification’ of blood, which may be understood to include the selling of or the 
making of profit from blood (WHO, 2009). Nevertheless, the processing of blood is 
associated with significant costs and results in a product that is of value in a clinical 
context. Subject to logistical and regulatory constraints, these products may be exchanged 
for a price across different national and regional health systems.
In cases where national health services operate an internal market, as is the case in 
England, the explicit charging of fees to hospitals for the supply of blood makes it easier 
to consider this issue. According to National Health Service Blood and Transplant 
(NHSBT, 2011), which is responsible for supplying blood to hospitals in England and 
North Wales, the charge to hospitals is currently £125 per unit. As far as we have been able 
to ascertain, most national blood services do not publish financial statements. However, 
these services all require specialist infrastructures and staff, and most have systems in 
place to recoup at least some of the costs of these. In these ways, blood products can 
acquire exchange value within the systems that supply and use them, notwithstanding the 
rules prohibiting the buying and selling of blood. Thus, the ideals surrounding voluntary 
blood donation do not prevent the generation of exchange value from donated blood.
Whereas it is difficult to obtain detailed information on the exchange value of blood 
products, when it comes to the suppliers of plasma products, more data are available. 
Healthy sales of plasma products have been reported by commercial plasma fractiona-
tors. According to a recent review:
The global market for plasma derived products, and recombinant alternatives, has a combined 
value of close to US$10.5 billion per annum. The market is dynamic, complex and highly 
competitive, and in respect of some products there is virtually unrestricted global trade. 
(Australian Government, 2006: 193)
Some of these products are highly valued for their clinical applications for patients 
with haemophilia and with rare or orphan diseases. Furthermore, as companies forge 
alliances with patient groups, they may secure the demand for their products and thereby 
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enhance the monetary value of these goods (CSL Limited, 2009). In addition to advocacy 
activities by, and on behalf of, a coalition of plasma users (patients) representing the 
interests of people with these diseases, EU research and development funds targeted at 
the treatment of rare diseases may facilitate the flow of funds towards these activities 
(Aymé and Hivert, 2011).
To sum up, the economic dimensions of the extensive trade in plasma are well docu-
mented; the availability of data is in part a consequence of the categorising of plasma 
products as pharmaceutical products and of their being supplied by commercial as well 
as not-for-profit agencies. On the contrary, the monetary value associated with the supply 
of blood components is not well documented and is difficult to quantify. These activities 
generally take place within state or non-profit organisations; the language used about the 
supply of blood by these organisations reflects the prohibition on the buying and selling 
of blood, the ethics of blood services, rather than trade, and is as a result rather opaque. 
Nevertheless, the supply of blood components is an expensive, complex and resource-
intensive activity, with diverse transactions taking place between donors and organisa-
tions involved in the procuring, processing and distribution of blood components. While 
the initial exchange is usually based on voluntary giving of the blood, the component 
parts subsequently acquire a price or exchange value.
The value of both plasma products and blood components is related to quality man-
agement. This in turn depends on demonstrable efforts being in place to screen the donor, 
donated blood and the inactivation of pathogens.8 Even with these measures in place, not 
all risks can be eliminated. Risks are frequently understood in epidemiological terms as 
related to donor population. Consequently, if the donor population is known, or assumed, 
to have a higher rate of any disease transmissible via blood, then the value of blood 
sourced from that population is likely to be greatly decreased. This is controversial not 
least because the evidence base for some such exclusion criteria has been subject to criti-
cism, as we have seen, for example, in relation to the exclusion of men who have sex 
with men from giving blood in blood services in many countries (Grenfell et al., 2011; 
Hurley, 2009). It has become evident that the social implications of exclusion as a blood 
donor may be highly problematic for those involved, especially if such policies are per-
ceived to be unjust or not merited.9
Risk and precaution in blood policy in the United 
Kingdom
Pathogens that have been considered a threat to blood safety over the past quarter century 
include those associated with HIV, malaria, Chagas disease, West Nile Virus and vCJD. 
As Farrugia has observed, the capacity of wealthier nations to deal with both established 
and emerging infections is impressive.10 However, ‘the key common feature of the main 
blood safety threats of the past quarter century has been their unpredictability’ (Farrugia, 
2009: 125). In common with a widely used terminology, we shall refer to infections that 
can be transmitted to recipients of donated blood as transfusion-transmissable infections 
(TTIs). As well as their unpredictability, the impact of these TTIs on the blood supply is 
shaped by the dynamics of globalisation including the international mobility of both 
people and products. Increasingly, new blood service requirements have created 
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categories of people (including sex workers, ‘men who have sex with men’, intravenous 
drug users and people who have travelled to specified geographic regions) who are not 
considered to be safe blood and plasma donors due to their being considered at higher 
risk of having infections. These measures, intended to enhance safety, have at times 
reduced the availability of blood, making it more difficult to access fresh blood for clini-
cal use, with adverse consequences for patient care (Farrugia, 2009).
An example of the problem of striking the right balance between safety and suffi-
ciency in the blood supply is the situation facing policymakers and regulators in the 
United Kingdom, where concerns arose that the presence of vCJD in the wider popula-
tion may be reflected in the blood donor population. Notwithstanding the considerable 
uncertainty around both the prevalence of the infective agent in the population and its 
transmission, a series of precautionary measures was put in place following recognition 
of this potential threat to blood safety (Lefrere and Hewitt, 2009). All the four UK blood 
services accepted the recommendation by the government’s advisory committee to 
import FFP from outside the United Kingdom for child patients (aged less than 16 years). 
FFP for these patients is therefore procured from the United States (Committee on the 
Safety of Blood, Tissues and Organs, 2012a). The use of UK-sourced plasma was allowed 
to continue for use for most adult patients, although this too was kept under review. 
Other measures have included a move to source plasma for the manufacture of plasma 
derivatives from outside the United Kingdom: BPL Ltd, a supplier of key plasma-derived 
products for the NHS, has been prohibited from processing plasma sourced from UK 
donors since 1998. One potential further measure that has been discussed is the possibil-
ity of introducing a test for the prion associated with vCJD, known as PrPSc, to the blood 
screening procedures, if a sufficiently sensitive and reliable test were to become availa-
ble (Bennett and Dobra, 2009). It is recognised, however, that the interests of donors and 
of recipients of blood may be somewhat different in relation to such a test: while strin-
gent screening is seen to be in the interests of patients, it may not be in the interests of 
donors to receive knowledge of a reactive test since interpretation of the implications of 
such a test is difficult at present and there is no known effective treatment for vCJD 
(Franklin, 2004). As well as leading to the ‘deferral’ (exclusion) of donors whose blood 
tested positive PrPSc, it is anticipated that some regular blood donors would choose not 
to continue if such a test were introduced (Bennett and Dobra, 2009).11 According to the 
UK governments’ advisory committee, recent data suggest that early estimates of preva-
lence of vCJD in the UK population may have been overly pessimistic (Committee on 
the Safety of Blood, Tissues and Organs, 2012b). Therefore, it was announced that while 
precautionary measures already implemented are being kept in place, some further meas-
ures that had been under active consideration would not be implemented at this time. 
Meanwhile, one wider consequence of these developments has been that people from the 
United Kingdom, or who have lived in the United Kingdom for significant periods, are 
prohibited from donating blood and plasma in many countries.
Although the incidence of vCJD in the population has presented a particular challenge 
to blood services in the United Kingdom, the policy response to this exemplifies the 
broader transition that has taken place from traditional blood banking primarily within 
national boundaries to international networks for the procurement and supply of blood 
products described above. First, the paradigm of national self-sufficiency in blood has 
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been eroded by the difficulties that many countries face in achieving a national supply, 
including logistical constraints, resource limitations and safety considerations. Second, 
there is a tension between the stated ideal of altruistic (unpaid) donation and the reality 
that the main global suppliers of plasma products pay donors in order to secure sufficient 
supplies of plasma. A third point brought out by these developments is that the assumed 
commonality of interests between donors and patients does not always hold true; at some 
critical points in the trajectory of the blood services, significant tensions may arise 
between the interests of donors and patients. Fourth, despite the dichotomy of blood 
components and plasma products, the common source of these in human blood means 
that ‘safety threats’ connect the two categories. Finally, the dilemma about the eventual 
implementation of tests for blood donors for vCJD infectivity offers an illustration of the 
trade-off between safety and supply in the blood supply: the imposition of higher safety 
thresholds, whether in relation to blood screening or the screening of donors, tends to 
reduce the supply of blood. In this context, the careful management of the limited 
resource of blood that conforms to a specified safety threshold becomes an important 
aspect of the tissue economy.
Conclusion: ethical relations in modern blood 
economies
Blood services are embedded in a narrative that is distinctly nostalgic, but the social rela-
tions between people who donate blood, people who need blood and people who work 
with blood have been transformed in the past 50 years (Busby, 2010). Despite common 
assumptions that ‘blood is blood’ – as patients and professionals are reported to have said, 
referring to the sheer ubiquity and mundaneness of blood in hospital settings (Pfeffer and 
Laws, 2006) – we have shown that such assumptions do not recognise key features of 
blood economies. Rather as we have seen blood is a material that is intensively processed, 
tested, discarded, used in short time or fractionated to be used in multiple products, made 
available to some patients, though not always in sufficient quantity or quality.
In the wake of the blood scandals of the 1980s, potential safety threats have been at 
the centre of contemporary public policy and risk management practices. Regulatory 
reform created a bifurcated approach to the regulation of blood and plasma and has 
sought to harmonise standards in the industry while also attempting to promote the ethi-
cal values that have traditionally shaped blood procurement practices (Farrell, 2009). 
This tension between the ethics of donation and the imperatives of ensuring a safe supply 
has had a number of effects, which we have outlined here. Potential threats to the blood 
supply and scarcity of blood products sometimes follow from interventions designed to 
reduce exposure to TTIs.
We also suggest that socio-ethical relations between donors and recipients in the 
blood economy have been transformed and merit closer consideration as do the ways 
in which ‘consumer’ interests are represented within the sector. The political stakes are 
high here as the need to protect public health is balanced with industry, professional 
and public or patient concerns. Donor deferral policies that exclude some groups from 
donating blood are just one arena where the politics of blood play out particular notions 
of risk.
Busby et al. 13
Finally, we suggest that social analysis of blood has neglected important aspects of 
what has increasingly become a global bioeconomy. The production of blood itself – far 
from being immutable – is both technically and socially complex. The often tacit pro-
cesses underlying blood sourcing and supply are deserving of continued vigilance and 
analysis because it will enrich both our understanding of how donor bodies are being 
revalued in the contemporary bioeconomy and how within this policy arena the tensions 
between safety and supply shape strategies for the governance of risk.
Funding
This work was supported by the UK Economic and Social Research Council [reference RES-062-
23-2751] and the Wellcome Trust [reference WT087439MF].
Notes
 1. This article is informed by an ongoing qualitative study about ‘Risk, safety and consent in 
blood services in the UK’, which aims to explore the framing and management of risk and 
safety in relation to blood transfusion by professionals, regulators, patients’ societies and peo-
ple who receive blood in the United Kingdom. We make particular reference to policy in the 
United Kingdom and to policy and law on blood safety in the European Union (EU), which 
strongly influences the UK regulatory environment. While reference is made to overviews of 
the international dimensions of blood economies, there is much important work about inter-
national policy on blood supply and blood safety that we have not been able to reference here, 
given the constraints of word limits. We have extended the focus on blood services to include 
some consideration of the supply and use of plasma for fractionation.
 2. In apheresis, blood is briefly extracted from the body, but only the plasma is collected for 
use while the red cells are returned to the donor. Plasma may also be sourced from donated 
(whole) blood.
 3. The donation of blood and plasma is subject to diverse rules in different countries. In the 
United States, plasma donors may receive monetary compensation. The global plasma indus-
try is highly reliant upon the United States for the supply of source plasma used in the manu-
facture of plasma derived products (Farrugia et al., 2010).
 4. The National Health Service Act 1946 (9 and 10 Geo 6. Ch. 81). London: HMSO.
 5. Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 
setting standards of quality and safety for the collection, testing, processing, storage and dis-
tribution of human blood and blood components and amending Directive 2001/83/EC.
 6. http://www.penroseinquiry.org.uk/preliminary-report/
 7. The Committee for the Safety of Blood, Tissues and Organs in the United Kingdom recently 
recommended that the policy of excluding men who have sex with men be changed to one of 
deferral for a fixed period (Hurley, 2011).
 8. In this article, we focus on the supply of blood products, rather than their administration. It 
should be noted, however, that the treatment context is known to be an important factor in 
transfusion safety. In the United Kingdom, for example, it is reported that patients are more 
likely to be put at risk by receiving the wrong blood component than by TTIs (Knowles and 
Cohen, 2011).
 9. We note that policies on donor exclusion are not necessarily contested or controversial: they 
may be characterised by a high degree of consensus. See Berner’s (2011: 384) consideration 
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of responses to the emerging threat posed by HIV by organisations representing gay men in 
Sweden in the 1980s.
10. World Health Organization (WHO, 2010) data show that donation rate and extent of viral 
testing are dependent on national economic status.
11. The blood services in the United Kingdom refer to the turning away of blood donors as ‘defer-
ral’, even if it is intended that they will be permanently excluded from donating blood.
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